Depression is one of the most widely misunderstood psychological conditions in the modern world. A lot of people simply assume that it’s about people feeling said. Unfortunately, it goes a lot deeper than that since it can mean a constant, crippling absence of any sensation related to happiness or satisfaction. In an effort to curtail the damage that this condition can do, a new app equipped with an artificial intelligence is being tested right now.
One of the most effective treatments for depression is talking to psychotherapists who will work with patients through their emotional distress. However, talking about depression is not easy and plenty of people often avoid it altogether. The new app called Woebot could provide an effective bridge in such situations by giving patients an avenue for a conversation with something that’s not human, Business Insider reports.
The app was created by Stanford University clinical psychologist Alison Darcy. According to her, Woebot was based on the treatment cognitive-behavioral therapy (CBT), which is intended to measure patient reactions to challenging scenarios. Darcy also notes that while Woebot can’t replace human therapists, it can still pave the way to recovery.
“What we haven’t done a good job of in [therapy] is give people an array of options — what about the people who aren’t ready to talk to another person?” Darcy said. “This is part of the idea of meeting people where they’re at.”
As to how effective the chatbot can even be, Darcy and her team published a study that showed a marked improvement in patients suffering from depression while interacting with Woebot. Naturally, more research is needed in order to make any kind of concrete conclusion with regards to using AI-powered chatbots as official psychological treatment tools.
However, this development does signal an encouraging direction in which therapists can go. The rate of suicide among teens and young adults has seen an alarming rise over recent years. This technology could pave the way to substantially reducing that.


Anthropic’s Claude Discovers CRISPR-Like Enzyme System
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
AMD Hits $1 Trillion as BofA Raises Price Target to $720
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns
Trump Signs Order to Cut Routine Childhood Vaccines
Meta Found Liable in New Mexico Facebook Data Privacy Case
Scott Bessent Eyed as Trump’s New AI Czar
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk
Apple Extends Qualcomm Patent Licensing Deal
US Appeals Court Upholds Anthropic AI Supply Chain Ban
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts
France Keeps Top Health Alert as Officials Brace for Another Heatwave
US Backs Musk in Fight Against EU’s €120 Million X Fine
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 



